Tirzepatide (Mounjaro®). HTA ID: 24003

Assessment Status Pre submission consultation scheduled
HTA ID 24003
Drug Tirzepatide
Brand Mounjaro®
Indication Tirzepatide (Mounjaro®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes.
Assessment Process
Rapid review commissioned 24/01/2024
Rapid review completed 06/02/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tirzepatide compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/03/2024